Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners

“Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy” webinar set for Tuesday, February 13, 2024 at 2:00 p.m. PST.


  • Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.
  • Optimi experts will address critical inquiries which still exist on the definition of validated GMP psilocybin, MDMA, and other psychedelic substances.
  • Optimi is the only end-to-end, publicly listed psychedelics company currently offering its drug candidates at scale to address accessibility through lower costs.

Vancouver, BC – February 6, 2023Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is announcing an informative webinar titled “Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy.” This event, scheduled for Tuesday, February 13, 2024, at 2:00 p.m. Pacific Standard Time (PST), is a crucial opportunity for clinicians, scientists, researchers, therapists, pharmacists, and regulators involved or interested in the GMP manufacturing of psychedelic drug substances.

The session will be hosted by Optimi Health Chief Science Officer, Dr. Preston A. Chase, and Director of Quality Commercial Strategies, Karina Lahnakoski. Both individuals, considered experts in their respective fields, currently lead the Company’s cutting-edge science and quality assurance divisions. The webinar aims to provide invaluable educational insights into the meticulous processes involved in ensuring the quality, safety, and international supply of the Company’s psychedelic drug candidates.

“Professionals aiming for a thorough grasp of the importance and impact of maintaining rigorous standards in psychedelic drug manufacturing and formulation are urged to attend,” stated Chase and Lahnakoski. “Our responsibility, extending from the laboratory to the patient, is to consistently achieve and uphold the utmost quality benchmark, gauged by accountability and trust. It is paramount for Optimi to showcase its leadership in the industry by highlighting unparalleled product quality and excellence, setting a standard for the world to witness.”

On December 12, 2023, Lykos, formerly known as the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation, submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking approval for MDMA-Assisted Therapy for PTSD. The FDA is expected to decide on the acceptance of the NDA by February 12, 2024. If accepted, a decision regarding the approval of the application is expected to be made within a timeframe of either six or 10 months.

This impending decision, as highlighted by Optimi CEO, Bill Ciprick, has the potential to reshape the industry landscape, presenting Optimi with a golden opportunity to showcase its preparedness in supplying globally validated GMP drug candidates.

Ciprick emphasizes, “Critical inquiries still exist regarding the safety, accessibility, cost, and supply of drugs necessary to meet the expected demand. We want this webinar to serve as a trustworthy guide for practitioners involved in global research and regulated patient access programs, as well as to share insights into the rigorous GMP quality standards, safety protocols, and production criteria crucial for ensuring exceptional patient care and optimal research outcomes.”

To register for the free webinar, please click on the link below or send an email to

Know Your Psychedelic Drug Candidate: Safeguarding Quality in Psychedelic Therapy.

For media inquiries, please contact Michael Kydd:

For investor inquiries, please contact:




Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

Optimi Health Corp. an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), natural GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug candidates throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.


Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca


This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form dated January 30, 2024, and other continuous disclosure filings available under Optimi’s profile at www.sedarplus.ca. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.

Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.